.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,388,104

« Back to Dashboard

Details for Patent: 9,388,104

Title:Chemically modified small molecules
Abstract: Provided are methods of preparing a monodisperse oligo (ethylene glycol) reagent composition.
Inventor(s): Bentley; Michael D. (Huntsville, AL), Viegas; Tacey X. (Madison, AL), Goodin; Richard R. (Fayetville, TN), Cheng; Lin (Huntsville, AL), Zhao; Xuan (Huntsville, AL)
Assignee: Nektar Therapeutics (San Francisco, CA)
Filing Date:Apr 08, 2014
Application Number:14/248,245
Claims:1. A method of preparing a monodisperse oligo (ethylene glycol) reagent composition, comprising: reacting a halo-terminated oligo (ethylene glycol) having (m) monomer subunits and a methoxy end-capping group with a first hydroxyl-terminated oligo (ethylene glycol) having (n) monomer subunits, wherein the first hydroxyl-terminated oligo (ethylene glycol) structure is HO--(CH.sub.2CH.sub.2O).sub.n--H, under conditions effective to displace said halo group to thereby form an oligo (ethylene glycol) having (m)+(n) monomer subunits (OEG.sub.m+n), wherein reacting the halo-terminated oligo(ethylene glycol) with the first hydroxyl-terminated oligo (ethylene glycol) comprises adding a 1:1 molar ratio of the halo-terminated oligo(ethylene glycol) to the first hydroxyl-terminated oligo (ethylene glycol) in a solution; converting the terminal hydroxyl group of OEG.sub.m+n into a halo group, --X, to form OEG.sub.m+n-X; and reacting OEG.sub.m+n-X with a second hydroxyl-terminated oligo (ethylene glycol) having (n) monomer subunits, wherein the second hydroxyl-terminated oligo structure is HO--(CH.sub.2CH.sub.2O).sub.n--H, under conditions effective to displace said halo group to thereby form an oligo(ethylene glycol) having (m)+2(n) monomer subunits (OEG.sub.m+2n), wherein reacting the OEG.sub.m+n-X with the second hydroxyl-terminated oligo (ethylene glycol) comprises adding a 1:1 molar ratio of the OEG.sub.m+n-X to the second hydroxyl-terminated oligo (ethylene glycol) in a solution; wherein (m) and (n) each independently range from 1-10, and wherein (OEG.sub.m+2n) corresponds to the structure CH.sub.3O(CH.sub.2CH.sub.2O).sub.m+2nH, and is present as part of a monodisperse composition of CH.sub.3O(CH.sub.2CH.sub.2O).sub.m+2nH.

2. A method of preparing a monodisperse oligo (ethylene glycol) reagent composition, comprising: reacting a halo-terminated oligo (ethylene glycol) having (m) monomer subunits and a methoxy end-capping group with a first hydroxyl-terminated oligo (ethylene glycol) having (n) monomer subunits, wherein the first hydroxyl-terminated oligo (ethylene glycol) structure is HO--(CH.sub.2CH.sub.2O).sub.n--H, under conditions effective to displace said halo group to thereby form an oligo (ethylene glycol) having (m)+(n) monomer subunits (OEG.sub.m+n), wherein reacting the halo-terminated oligo(ethylene glycol) with the first hydroxyl-terminated oligo (ethylene glycol) comprises adding a 1:1 molar ratio of the halo-terminated oligo(ethylene glycol) to the first hydroxyl-terminated oligo (ethylene glycol) in a solution; converting the terminal hydroxyl group of OEG.sub.m+n into a halo group, --X, to form OEG.sub.m+n-X; reacting OEG.sub.m+n-X with a second hydroxyl-terminated oligo (ethylene glycol) having (n) monomer subunits under conditions effective to displace said halo group to thereby form an oligo(ethylene glycol) having (m)+2(n) monomer subunits (OEG.sub.m+2n), wherein OEG.sub.m+2n possesses a primary or secondary hydroxyl group, wherein reacting the OEG.sub.m+n-X with the second hydroxyl-terminated oligo (ethylene glycol) comprises adding a 1:1 molar ratio of the OEG.sub.m+n-X to the second hydroxyl-terminated oligo (ethylene glycol) in a solution; converting said primary or secondary hydroxyl group into a halo group, --X, to form OEG.sub.m+2n-X; and reacting OEG.sub.m+2n-X with a third hydroxyl-terminated oligo (ethylene glycol) having (n) monomer subunits under conditions effective to displace said halo group to thereby form an oligo (ethylene glycol) having m+3n monomer subunits (OEG.sub.m+3n), wherein reacting the OEG.sub.m+2n-X with the third hydroxyl-terminated oligo (ethylene glycol) comprises adding a 1:1 molar ratio of the OEG.sub.m+2n-X to the third hydroxyl-terminated oligo (ethylene glycol) in a solution; wherein (m) and (n) each independently range from 1-10; and wherein (OEG.sub.m+3n) corresponds to the structure CH.sub.3O(CH.sub.2CH.sub.2O).sub.m+3nH, and is present as a monodisperse composition of CH.sub.3O(CH.sub.2CH.sub.2O).sub.m+3nH.

3. The method of claim 1, wherein (m) ranges from 1-3 and (n) ranges from 2-6.

4. The method of claim 2, wherein (m) ranges from 1-3 and (n) ranges from 2-6.

5. The method of claim 1, wherein each reacting step is carried out in the presence of a strong base.

6. The method of claim 2, wherein each reacting step is carried out in the presence of a strong base.

7. The method of claim 1, wherein each of the halo groups is Br.

8. The method of claim 2, wherein each of the halo groups is Br.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc